| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | Amicus Therapeutics, Inc.: Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook | 159 | GlobeNewswire (Europe) | 2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® + Opfolda® Total Revenue Growth of 17-24% at CER Expected... ► Artikel lesen | |
| 12.01. | Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results | 110 | GlobeNewswire (Europe) | New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted... ► Artikel lesen | |
| 12.01. | Mereo BioPharma Group plc: Mereo BioPharma Provides Update on Lead Clinical Programs | 296 | GlobeNewswire (Europe) | Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease... ► Artikel lesen | |
| 12.01. | Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones | 82 | GlobeNewswire (Europe) | Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to $89... ► Artikel lesen | |
| 12.01. | RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance | 197 | GlobeNewswire (Europe) | ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen | |
| 12.01. | Arcutis Biotherapeutics, Inc.: Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million | 183 | GlobeNewswire (Europe) | Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366% vs. Q4 2023 and 41% vs. Q3 2024Preliminary unaudited product... ► Artikel lesen | |
| 12.01. | Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer | 447 | GlobeNewswire (Europe) | New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to tenExpanded partnership highlights the parties'... ► Artikel lesen | |
| 12.01. | Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference | 523 | GlobeNewswire (Europe) | Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025Mesothelin named as second target in Radio-DARPin pipeline, program to be co-developed with Orano... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NVIDIA | 3.010 |
| APPLE | 2.123 |
| STEYR MOTORS | 1.950 |
| RHEINMETALL | 1.715 |
| BYD | 1.529 |
| RENK GROUP | 1.291 |
| TESLA | 1.241 |
| TUI | 1.190 |
| DEUTZ | 1.101 |
| NEL | 888 |
| NOVO NORDISK | 733 |
| EVOTEC | 727 |
| INFINEON | 702 |
| BASF | 669 |
| BAYER | 624 |
| MERCEDES-BENZ | 616 |
| DEUTSCHE BANK | 607 |
| XIAOMI | 600 |
| MUTARES | 567 |
| THYSSENKRUPP | 565 |
| COMMERZBANK | 555 |
| ALLIANZ | 553 |
| AMAZON | 553 |
| DEUTSCHE TELEKOM | 553 |
| VOLKSWAGEN | 553 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
